Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, has received a European Patent for treating travelers' diarrhea. The patent, granted on January 5, 2022, covers 'Composition and method for the treatment and prevention of enteric bacterial infections.' This extends Immuron's patent coverage across multiple regions, including Australia, India, Canada, and the US. Given the rising antibiotic resistance in enteric pathogens, this patent validates a preventative approach that addresses a critical health issue prevalent among travelers and military personnel.

Positive

• Granted European Patent 3159357 for treating travelers' diarrhea, expanding market potential.
• Patent validated in key European countries like France, Spain, and Germany.

Negative

• None.

MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has been granted a European Patent for compositions and methods for treating travelers’ diarrhea.

European Patent 3159357, entitled “Composition and method for the treatment and prevention of enteric bacterial infections”, was granted on January 5, 2022.

Immuron is validating the patent in the following European member states, France, Spain, Sweden, Austria, Germany, Denmark, Finland, Greece and United Kingdom. The European registration adds to Immuron's patent position for compositions and methods for treating travelers’ diarrhea in Australia, India, Canada and the Unites States.

Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. The morbidity and associated discomfort stemming from diarrhea decreases daily performance, affects judgment, decreases morale, and declines operational readiness. The first line of treatment for infectious diarrhea is the prescription of antibiotics. Unfortunately, in the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics. In addition, travelers' diarrhea is now recognized by the medical community to result in post-infectious sequelae, including post-infectious irritable bowel syndrome and several post-infectious autoimmune diseases. A preventative treatment that protects against enteric diseases is a high priority objective for the US Military.

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT: Dr Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com

US INVESTOR CONTACT Dave Gentry, CEO RedChip Companies Inc. +1-407-491-4498 dave@redchip.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com

FAQ

What is the significance of Immuron's new European Patent?

Immuron's European Patent allows for the development and commercialization of treatments for travelers' diarrhea, enhancing its market presence.

When was the European Patent for Immuron granted?

The European Patent was granted on January 5, 2022.

What are the implications of antibiotic resistance for Immuron's product?

The increasing resistance of pathogens to antibiotics highlights the need for Immuron's preventative treatment against travelers' diarrhea.

Which countries are included in Immuron's patent validation?

The patent has been validated in France, Spain, Sweden, Austria, Germany, Denmark, Finland, Greece, and the United Kingdom.

How does Immuron's patent benefit the US Military?

The preventative treatment is a high priority for the US Military to enhance operational readiness among troops.